Analyst Daniel Brennan of TD Cowen maintained a Buy rating on Thermo Fisher, boosting the price target to $654.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Brennan’s rating is based on Thermo Fisher’s strong performance in the third quarter, where the company exceeded earnings expectations by 5% and showed slight organic growth. The biopharma sector, a key market for Thermo Fisher, demonstrated mid-single-digit growth, reinforcing confidence in the company’s future prospects. This sector’s strength, along with improvements in biotech and PPD, supports a positive outlook for 2026.
Additionally, Thermo Fisher’s management raised the revenue and EPS guidance for fiscal year 2025, driven by favorable foreign exchange impacts and contributions from acquisitions. Despite some challenges, such as a decline in U.S. academic and government customer activity, the overall stability and signs of improvement in the company’s performance have led to a positive market response. Brennan’s Buy rating reflects the potential for further growth and an increase in the stock’s multiple if organic growth trends continue to improve.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $605.00 price target.